155 related articles for article (PubMed ID: 38155484)
1. Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.
Gurumurthy G; Kisiel F; Gurumurthy S; Gurumurthy J
J Oncol Pharm Pract; 2023 Dec; ():10781552231219003. PubMed ID: 38155484
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
Zhang X; Chuai Y; Nie W; Wang A; Dai G
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
[TBL] [Abstract][Full Text] [Related]
3. Emerging data on thrombopoietin receptor agonists for management of chemotherapy-induced thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Hematol; 2023 May; 16(5):365-375. PubMed ID: 37039010
[TBL] [Abstract][Full Text] [Related]
4. Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists.
Gilreath J; Lo M; Bubalo J
Drugs; 2021 Jul; 81(11):1285-1305. PubMed ID: 34160821
[TBL] [Abstract][Full Text] [Related]
5. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
6. Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists.
Al-Samkari H
Blood Rev; 2024 Jan; 63():101139. PubMed ID: 37914568
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of thrombopoietin receptor agonists in solid tumors with chemotherapy-induced thrombocytopenia: a meta-analysis.
Chen W; Liu Y; Li L; Zeng X
BMC Pharmacol Toxicol; 2023 Dec; 24(1):71. PubMed ID: 38041150
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin level predicts response to treatment with romiplostim in chemotherapy-induced thrombocytopenia.
Song AB; Goodarzi K; Karp Leaf R; Kuter DJ; Al-Samkari H
Am J Hematol; 2021 Dec; 96(12):1563-1568. PubMed ID: 34453757
[TBL] [Abstract][Full Text] [Related]
9. An updated evaluation of avatrombopag for the treatment of chronic immune thrombocytopenia.
Song AB; Al-Samkari H
Expert Rev Clin Immunol; 2022 Aug; 18(8):783-791. PubMed ID: 35793401
[TBL] [Abstract][Full Text] [Related]
10. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
11. European Delphi panel to build consensus on tapering and discontinuing thrombopoietin receptor agonists in immune thrombocytopenia.
Barlassina A; González-López TJ; Cooper N; Zaja F
Platelets; 2023 Dec; 34(1):2170999. PubMed ID: 36803535
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy and Safety of Thrombopoietin Receptor Agonists in Adults With Thrombocytopenia: A Systematic Review and Network Meta-analysis of Randomized Controlled Trial.
Deng J; Hu H; Huang F; Huang C; Huang Q; Wang L; Wu A; Yang J; Qin D; Zou W; Wu J
Front Pharmacol; 2021; 12():704093. PubMed ID: 34393785
[TBL] [Abstract][Full Text] [Related]
13. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia.
González-Porras JR; Godeau B; Carpenedo M
Ther Adv Hematol; 2019; 10():2040620719837906. PubMed ID: 31156798
[TBL] [Abstract][Full Text] [Related]
14. Thrombopoietin-receptor agonists for adult patients with immune thrombocytopenia: a narrative review and an approach for managing patients fasting intermittently.
Yassin MA; Al-Rasheed M; Al-Khaboori M; Marashi M; Osman H; Wali Y; Al Kindi S; Alsayegh F; Provan D
Front Cardiovasc Med; 2023; 10():1260487. PubMed ID: 38162126
[TBL] [Abstract][Full Text] [Related]
15. Romiplostim.
Kuter DJ
Cancer Treat Res; 2011; 157():267-88. PubMed ID: 21052962
[TBL] [Abstract][Full Text] [Related]
16. Romiplostim for management of chemotherapy-induced thrombocytopenia.
Parameswaran R; Lunning M; Mantha S; Devlin S; Hamilton A; Schwartz G; Soff G
Support Care Cancer; 2014 May; 22(5):1217-22. PubMed ID: 24414994
[TBL] [Abstract][Full Text] [Related]
17. Management of chemotherapy-induced thrombocytopenia: guidance from the ISTH Subcommittee on Hemostasis and Malignancy.
Soff G; Leader A; Al-Samkari H; Falanga A; Maraveyas A; Sanfilippo K; Wang TF; Zwicker J
J Thromb Haemost; 2024 Jan; 22(1):53-60. PubMed ID: 37827380
[TBL] [Abstract][Full Text] [Related]
18. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease.
Khemichian S; Terrault NA
Semin Thromb Hemost; 2020 Sep; 46(6):682-692. PubMed ID: 32820479
[TBL] [Abstract][Full Text] [Related]
20. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus.
Pulanić D; Bátorová A; Bodó I; Červinek L; Ionita I; Lissitchkov T; Melikyan A; Podolak-Dawidziak M
Ann Hematol; 2023 Apr; 102(4):715-727. PubMed ID: 36826482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
